Levetiracetam SUN 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IB/0030 
B.II.f.1.d - Stability of FP - Change in storage 
19/09/2023 
conditions of the finished product or the 
diluted/reconstituted product 
amended 
on 
SmPC, 
Labelling and 
PL 
IB/0029/G 
This was an application for a group of variations. 
16/08/2023 
SmPC and PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0028 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/06/2022 
26/05/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0027 
B.II.e.7.b - Change in supplier of packaging 
05/04/2022 
n/a 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
II/0026 
B.I.z - Quality change - Active substance - Other 
16/12/2021 
n/a 
variation 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/05/2021 
04/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IAIN/0024 
B.II.b.1.a - Replacement or addition of a 
27/01/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0023/G 
This was an application for a group of variations. 
19/01/2021 
18/03/2021 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0022 
Minor change in labelling or package leaflet not 
02/10/2020 
18/03/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0021 
B.II.b.1.a - Replacement or addition of a 
29/06/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/03/2020 
18/03/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/09/2019 
24/10/2019 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IA/0018 
B.II.e.3.b - Change in test procedure for the 
13/08/2019 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
IB/0017/G 
This was an application for a group of variations. 
26/10/2018 
24/10/2019 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0016 
Minor change in labelling or package leaflet not 
24/07/2018 
24/10/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0015 
Minor change in labelling or package leaflet not 
28/11/2017 
20/12/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/01/2017 
20/12/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0013 
Renewal of the marketing authorisation. 
15/09/2016 
14/11/2016 
Annex II and 
Based on the review of data on quality, safety and efficacy, 
PL 
the CHMP considered that the benefit-risk balance of 
Levetiracetam SUN in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/04/2016 
14/11/2016 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0011 
A.4 - Administrative change - Change in the name 
27/01/2016 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0010 
C.I.8.a - Introduction of or changes to a summary of 
28/10/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
II/0008 
B.II.b.4.d - Change in the batch size (including batch 
22/10/2015 
n/a 
size ranges) of the finished product - The change 
relates to all other pharmaceutical forms 
manufactured by complex manufacturing processes 
IB/0009/G 
This was an application for a group of variations. 
03/06/2015 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
IB/0007/G 
This was an application for a group of variations. 
28/03/2014 
06/02/2015 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0006 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
14/02/2014 
06/02/2015 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0005 
C.I.8.a - Introduction of or changes to a summary of 
21/11/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/11/2013 
18/12/2013 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0003 
Minor change in labelling or package leaflet not 
20/03/2013 
18/12/2013 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0002 
B.II.e.7.b - Change in supplier of packaging 
16/01/2013 
18/12/2013 
SmPC 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/07/2012 
31/10/2012 
SmPC, 
Update of SmPC section 4.8 to bring it in line with SmPC for 
generic/hybrid/biosimilar products following 
Labelling and 
the originator in order to add 'panic attack' as an 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
PL 
undesirable effect following the cumulative review of the 
safety data for Keppra as requested by CHMP.  
In addition, editorial changes were made to sections 2 and 
4.4 in order to change the description of the quantity of the 
sodium excipient in Levetiracetam SUN concentrate for 
solution for infusion. Sections 8, 9 and 10 of the SmPC 
were also updated. 
The Package Leaflet was updated in accordance. 
Editorial changes were also made to Annex IIIA.  
Moreover, the description of pancytopenia, erythema 
multiforme, Stevens-Johnsons syndrome and toxic 
epidermal necrolysis in section 4 of the Package Leaflet was 
added together with an update of local representatives. 
Furthermore, the PI is brought in line with the latest QRD 
template, version 8. 
Page 8/8 
 
 
 
 
 
 
 
 
